<?xml version='1.0' encoding='utf-8'?>
<document id="31957507"><sentence text="Evaluating emtricitabine + rilpivirine + tenofovir alafenamide in combination for the treatment of HIV-infection."><entity charOffset="11-62" id="DDI-PubMed.31957507.s1.e0" text="emtricitabine + rilpivirine + tenofovir alafenamide" /></sentence><sentence text="Introduction: Antiretroviral therapy (ART) is recommended for all people who are living with HIV to suppress viral load and to stop the progression and transmission of HIV-1" /><sentence text=" Fixed-dose combinations of antiretrovirals largely reduce pill burden" /><sentence text="Areas covered: The authors first provide an overview of the use of non-nucleoside reverse transcriptase inhibitor (NNRTI) based therapy in HIV care" /><sentence text=" They then summarize the properties of each drug in the fixed-dose combination of tenofovir alafenamide/emtricitabine/rilpivirine/(TAF/FTC/RPV)"><entity charOffset="82-103" id="DDI-PubMed.31957507.s5.e0" text="tenofovir alafenamide" /><entity charOffset="104-117" id="DDI-PubMed.31957507.s5.e1" text="emtricitabine" /><entity charOffset="118-129" id="DDI-PubMed.31957507.s5.e2" text="rilpivirine" /><entity charOffset="135-138" id="DDI-PubMed.31957507.s5.e3" text="FTC" /><pair ddi="false" e1="DDI-PubMed.31957507.s5.e0" e2="DDI-PubMed.31957507.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31957507.s5.e0" e2="DDI-PubMed.31957507.s5.e1" /><pair ddi="false" e1="DDI-PubMed.31957507.s5.e0" e2="DDI-PubMed.31957507.s5.e2" /><pair ddi="false" e1="DDI-PubMed.31957507.s5.e0" e2="DDI-PubMed.31957507.s5.e3" /><pair ddi="false" e1="DDI-PubMed.31957507.s5.e1" e2="DDI-PubMed.31957507.s5.e1" /><pair ddi="false" e1="DDI-PubMed.31957507.s5.e1" e2="DDI-PubMed.31957507.s5.e2" /><pair ddi="false" e1="DDI-PubMed.31957507.s5.e1" e2="DDI-PubMed.31957507.s5.e3" /><pair ddi="false" e1="DDI-PubMed.31957507.s5.e2" e2="DDI-PubMed.31957507.s5.e2" /><pair ddi="false" e1="DDI-PubMed.31957507.s5.e2" e2="DDI-PubMed.31957507.s5.e3" /></sentence><sentence text=" The efficacy and safety of each component and the combination as a whole are reviewed: FTC is non-inferior to lamivudine (3TC) at assessed dosages; TAF was non-inferior to tenofovir disoproxil fumarate (TDF); the viral efficacy of RPV is non-inferior with EFV at the assessed dosage; TAF/FTC/RPV is non-inferior in efficacy but shows less of a decline in bone mineral density and renal function compared to TDF/FTC/RPV"><entity charOffset="111-121" id="DDI-PubMed.31957507.s6.e0" text="lamivudine" /><entity charOffset="123-126" id="DDI-PubMed.31957507.s6.e1" text="3TC" /><entity charOffset="149-152" id="DDI-PubMed.31957507.s6.e2" text="TAF" /><entity charOffset="173-202" id="DDI-PubMed.31957507.s6.e3" text="tenofovir disoproxil fumarate" /><entity charOffset="204-207" id="DDI-PubMed.31957507.s6.e4" text="TDF" /><entity charOffset="88-90" id="DDI-PubMed.31957507.s6.e5" text="FTC" /><entity charOffset="289-291" id="DDI-PubMed.31957507.s6.e6" text="FTC" /><entity charOffset="412-414" id="DDI-PubMed.31957507.s6.e7" text="FTC" /><entity charOffset="285-287" id="DDI-PubMed.31957507.s6.e8" text="TAF" /><entity charOffset="408-410" id="DDI-PubMed.31957507.s6.e9" text="TDF" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e5" e2="DDI-PubMed.31957507.s6.e5" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e5" e2="DDI-PubMed.31957507.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e5" e2="DDI-PubMed.31957507.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e5" e2="DDI-PubMed.31957507.s6.e2" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e5" e2="DDI-PubMed.31957507.s6.e3" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e5" e2="DDI-PubMed.31957507.s6.e4" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e5" e2="DDI-PubMed.31957507.s6.e8" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e5" e2="DDI-PubMed.31957507.s6.e6" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e5" e2="DDI-PubMed.31957507.s6.e9" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e5" e2="DDI-PubMed.31957507.s6.e7" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e0" e2="DDI-PubMed.31957507.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e0" e2="DDI-PubMed.31957507.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e0" e2="DDI-PubMed.31957507.s6.e2" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e0" e2="DDI-PubMed.31957507.s6.e3" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e0" e2="DDI-PubMed.31957507.s6.e4" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e0" e2="DDI-PubMed.31957507.s6.e8" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e0" e2="DDI-PubMed.31957507.s6.e6" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e0" e2="DDI-PubMed.31957507.s6.e9" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e0" e2="DDI-PubMed.31957507.s6.e7" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e1" e2="DDI-PubMed.31957507.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e1" e2="DDI-PubMed.31957507.s6.e2" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e1" e2="DDI-PubMed.31957507.s6.e3" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e1" e2="DDI-PubMed.31957507.s6.e4" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e1" e2="DDI-PubMed.31957507.s6.e8" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e1" e2="DDI-PubMed.31957507.s6.e6" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e1" e2="DDI-PubMed.31957507.s6.e9" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e1" e2="DDI-PubMed.31957507.s6.e7" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e2" e2="DDI-PubMed.31957507.s6.e2" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e2" e2="DDI-PubMed.31957507.s6.e3" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e2" e2="DDI-PubMed.31957507.s6.e4" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e2" e2="DDI-PubMed.31957507.s6.e8" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e2" e2="DDI-PubMed.31957507.s6.e6" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e2" e2="DDI-PubMed.31957507.s6.e9" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e2" e2="DDI-PubMed.31957507.s6.e7" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e3" e2="DDI-PubMed.31957507.s6.e3" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e3" e2="DDI-PubMed.31957507.s6.e4" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e3" e2="DDI-PubMed.31957507.s6.e8" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e3" e2="DDI-PubMed.31957507.s6.e6" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e3" e2="DDI-PubMed.31957507.s6.e9" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e3" e2="DDI-PubMed.31957507.s6.e7" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e4" e2="DDI-PubMed.31957507.s6.e4" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e4" e2="DDI-PubMed.31957507.s6.e8" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e4" e2="DDI-PubMed.31957507.s6.e6" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e4" e2="DDI-PubMed.31957507.s6.e9" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e4" e2="DDI-PubMed.31957507.s6.e7" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e8" e2="DDI-PubMed.31957507.s6.e8" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e8" e2="DDI-PubMed.31957507.s6.e6" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e8" e2="DDI-PubMed.31957507.s6.e9" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e8" e2="DDI-PubMed.31957507.s6.e7" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e6" e2="DDI-PubMed.31957507.s6.e6" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e6" e2="DDI-PubMed.31957507.s6.e9" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e6" e2="DDI-PubMed.31957507.s6.e7" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e9" e2="DDI-PubMed.31957507.s6.e9" /><pair ddi="false" e1="DDI-PubMed.31957507.s6.e9" e2="DDI-PubMed.31957507.s6.e7" /></sentence><sentence text=" Finally, adverse effects and drug-drug interaction data with FTC/RPV/TAF are discussed"><entity charOffset="62-64" id="DDI-PubMed.31957507.s7.e0" text="FTC" /><entity charOffset="70-72" id="DDI-PubMed.31957507.s7.e1" text="TAF" /><pair ddi="false" e1="DDI-PubMed.31957507.s7.e0" e2="DDI-PubMed.31957507.s7.e0" /><pair ddi="false" e1="DDI-PubMed.31957507.s7.e0" e2="DDI-PubMed.31957507.s7.e1" /></sentence><sentence text="Expert opinion: TAF/FTC/RPV can be used as an initial regimen for people living with HIV whose HIV RNA &lt;100,000 copies/ml and CD4 cell count &gt; 200 cells/mm3 when INSTI-based regimens are not a treatment option"><entity charOffset="20-22" id="DDI-PubMed.31957507.s8.e0" text="FTC" /><entity charOffset="16-18" id="DDI-PubMed.31957507.s8.e1" text="TAF" /><pair ddi="false" e1="DDI-PubMed.31957507.s8.e1" e2="DDI-PubMed.31957507.s8.e1" /><pair ddi="false" e1="DDI-PubMed.31957507.s8.e1" e2="DDI-PubMed.31957507.s8.e0" /></sentence><sentence text=" Future antiretroviral therapy development may focus on dual therapy-based regimens containing RPV, particularly as long-acting formulations" /><sentence text="" /></document>